Actively Recruiting
Phase 1 Study of 18FDK222 PETCT Imaging for Patients With Non-Small Cell Lung Cancer and Urothelial Cancer Eligible for Anti-PDL-1 Treatment
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2026-07-28
6
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a new drug called 18FDK222 in people with non-small cell lung cancer NSCLC or urothelial cancer UC. This Phase 1 clinical trial aims to gather early information on the safety of 18FDK222, how it spreads through the body, how long it remains, and the amount of radiation it emits. The drug targets a protein called PD-L1, which can help cancer avoid detection by the immune system. Participants will receive an injection of the investigational radiotracer 18FDK222 through a vein. After administration, they will undergo a PET-CT scan to see where the drug accumulates in the body. This is an open-label, single-arm study focused on assessing the safety and diagnostic performance of the radiotracer. During the study, participants will be monitored for any adverse events up to 10 days after receiving the injection. Researchers will evaluate safety by tracking any severe side effects. The trial will include laboratory tests, imaging scans, and clinical assessments to measure how well the radiotracer performs and to ensure participant safety throughout the study period, which lasts until September 2027.
CONDITIONS
Brief Title
DK222 Study at Hopkins
Research Team
M
Mehreen Nabi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
